Multi-parametric Integrated Molecular Detection of SARS-CoV-2 from Biofluids by Adapting Single Extracellular Vesicle Characterization Technologies
采用单细胞外囊泡表征技术对生物体液中的 SARS-CoV-2 进行多参数集成分子检测
基本信息
- 批准号:10320988
- 负责人:
- 金额:$ 87.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-12-21 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVACE2AntibodiesAntibody ResponseAwardBiological AssayBiological ModelsBiometryBiotechnologyBody FluidsBypassCOVID-19COVID-19 detectionCOVID-19 diagnosisCOVID-19 patientCOVID-19 testCellsCharacteristicsClinicalClinical MicrobiologyColumn ChromatographyCommunicable DiseasesCommunicationCoronavirusDetectionDevelopmentDevicesDiagnosisDiseaseDoctor of PhilosophyDocumentationEmergency SituationEngineeringEnzyme-Linked Immunosorbent AssayFDA Emergency Use AuthorizationFluorescenceGlycoproteinsHealthcareHospitalsHumanImmunoglobulin GImmunoglobulin MIn SituIndividualInfectionInstitutesKnowledgeLabelLaboratoriesLicensingLocationMeasurementMediatingMedical centerMembraneMembrane ProteinsMethodsMicrofluidicsMolecularMolecular Sieve ChromatographyNanotechnologyNatureNucleic Acid Amplification TestsNucleic AcidsOhioParticulatePatientsPhasePhysiciansPlasmaPneumoniaPolymerase Chain ReactionPopulationProductionProteinsRNARNA VirusesRadiologic HealthReaderResearch PersonnelRetroviridaeReverse TranscriptionRiskSARS-CoV-2 exposureSARS-CoV-2 positiveSalivaSamplingSensitivity and SpecificitySerology testSerumServicesSignal TransductionSorting - Cell MovementSpeedSurfaceSystemSystems BiologyTechnologyTestingUnited States National Institutes of HealthUniversitiesValidationVesicleViralViral AntibodiesViral Load resultViral ProteinsVirusWorld Health Organizationantigen testbasebiochipcommercializationcomparativedesigndetection methodemerging pathogenexosomeexperienceexperimental studyextracellularextracellular vesiclesfluorescence microscopeimprovedinterestisothermal amplificationmicrofluidic technologymultidisciplinarynanobiotechnologynanofabricationnasopharyngeal swabnew technologynovel coronaviruspandemic diseaseparticlepoint of careprognosticprotein expressionresearch clinical testingsaliva samplesample collectionscale upstandard of careviral RNAviral detection
项目摘要
Abstract
The World Health Organization has recognized a global pandemic of novel coronavirus pneumonia (COVID-19)
from exposure to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronaviruses (CoVs)
are membrane-enveloped positive-sense, single-stranded RNA viruses decorated with membrane proteins. The
spike (S) glycoprotein is implicated in the viral attachment and fusion to host cells via the human angiotensin-
converting enzyme 2 (hACE2). There are different assays to test for COVID-19, including nucleic acid, antigen,
and serological tests that can be used in hospitals, point-of-care, and large-scale population testing. Nucleic acid
testing is the standard method for the detection of SARS-CoV-2, which consists of the amplification of viral RNA
from nasopharyngeal swabs (NPS) by quantitative reverse-transcription polymerase chain reaction (qRT-PCR).
Furthermore, given the invasive nature of NPS, saliva is being considered an alternative for detection. Methods
that bypass RNA extraction, as well as isothermal amplification such as loop-mediated isothermal amplification
(LAMP), have been developed to improve the speed of viral RNA detection. However, viral protein expression
cannot be detected by qRT-PCR. Serological tests, on the other hand, are based on host antibodies against the
virus (IgG/IgM). Although fast, these tests suffer from significant false negative/positive. Besides, they do not
detect a current infection. Therefore, to relieve the current healthcare crisis, new technologies capable of
simultaneous viral RNA/protein detection at the single virus level and host antibody response detection from a
body fluid in an integrated device would be highly valuable for enhanced COVID-19 diagnosis.
Recently, our group, as part of Phase 2 of the Extracellular RNA Communication Consortium (ERCC2), has
successfully developed a microfluidics technology capable of capturing individual exosomes from biofluids and
then simultaneously quantify both exosomal surface proteins and RNA cargo. Given the resemblance in size
and other characteristics between exosomes and coronaviruses, our technology can be adapted for COVID-19
diagnosis. Therefore, we propose to develop and validate a safe-to-use version of our microfluidics system for
direct detection of SARS-CoV-2. The integrated system is capable of multi-parametric detection for enhanced
COVID-19 diagnosis. The platform will be engineered to simultaneously quantify both viral protein, viral RNA,
and host antibodies (IgG/IgM) in the same sample, enabling diagnosis, disease status, and prognostic
assessment. Model systems, including host IgG/IgM from patient serum, standard synthetic vesicles (SVs), and
heat-inactivated SARS-CoV-2 viral particles (SVVs), will be designed and spiked in biofluids to validate and
calibrate the system. To demonstrate the clinical utility, our biochip technology will be deployed and tested using
different biofluids from COVID-19 patients at two independent laboratories (Institute of Systems Biology in
Seattle and The Ohio State University (OSU) Wexner Medical Center in Columbus). Measurements obtained
from the biochips will be compared to standard qRT-PCR and ELISA methods. A transition plan will be prepared
for FDA Emergency Use Authorization (EUA) application of the biochip technology through a COVID-19 clinical
testing laboratory at OSU Wexner Medical Center. A commercialization plan will also be developed via licensing
to a biotech company.
We have assembled a multi-disciplinary team with extensive knowledge and experience in nanobiotechnology,
microfluidics, micro/nano-fabrication, infectious diseases, and clinical COVID-19 patient sample collection and
testing. The proposed aims and milestones are given as follows:
Specific Aim 1: Development of an integrated biochip to simultaneously capture, fix, and characterize
single SARS-CoV-2 and IgG/IgM proteins. Milestones. (i) Sorting, capture, and quantitative analysis of
selected proteins and viral RNA in single virus in spike experiments with >95% repeatability; (ii) A sensitivity of
single virus detection with >90% repeatability and 5-fold better sensitivity than the current qRT-PCR and ELISA
methods. Specific Aim 2: Testing of single SARS-CoV-2 virus and associated IgG/IgM in biofluids from
COVID-19 patients. Milestones. (i) Quantitative analysis of clinical samples with >95% repeatability; (ii) 95%
of concordance for the detection of SARS-CoV-2 between the biochip technology and the lab-based qRT-PCR
and ELISA. Specific Aim 3: Biochip technology transition plan. Milestones. (i) Submission of documentation
to the FDA Center for Devices and Radiological Health (CDRH) for EUA; (ii) Scale-up commercialization plan for
GMP chip production.
摘要
世界卫生组织已确认新型冠状病毒肺炎(COVID-19)全球大流行
严重急性呼吸道综合征冠状病毒2(SARS-CoV-2)。冠状病毒(CoV)
是膜包膜正义单链RNA病毒,修饰有膜蛋白。的
刺突(S)糖蛋白参与病毒通过人血管紧张素-
转化酶2(hACE 2)。有不同的检测方法来检测COVID-19,包括核酸,抗原,
以及可用于医院、护理点和大规模人群检测的血清学检测。核酸
检测是检测SARS-CoV-2的标准方法,包括病毒RNA的扩增
通过定量逆转录聚合酶链反应(qRT-PCR)从鼻咽拭子(鼻咽拭子)中获得。
此外,鉴于唾液的侵入性,唾液被认为是检测的替代品。方法
其绕过RNA提取,以及等温扩增如环介导等温扩增
(LAMP),已经被开发用于提高病毒RNA检测的速度。然而,病毒蛋白表达
不能通过qRT-PCR检测。另一方面,血清学测试是基于针对
病毒(IgG/IgM)。虽然快速,但这些测试遭受显著的假阴性/阳性。此外,他们不
检测当前感染。因此,为了缓解当前的医疗危机,能够
在单一病毒水平上同时检测病毒RNA/蛋白质,并从
集成设备中的体液对于增强COVID-19诊断非常有价值。
最近,我们的小组,作为细胞外RNA通讯联盟(ERCC 2)第2阶段的一部分,
成功开发了能够从生物流体中捕获单个外泌体的微流体技术,
然后同时定量外泌体表面蛋白和RNA货物。鉴于大小相似
以及外泌体和冠状病毒之间的其他特征,我们的技术可以适用于COVID-19
诊断.因此,我们建议开发和验证我们的微流体系统的安全使用版本,
直接检测SARS-CoV-2该集成系统能够进行多参数检测,
COVID-19诊断该平台将被设计为同时定量病毒蛋白,病毒RNA,
和宿主抗体(IgG/IgM)在同一样品中,使诊断,疾病状态,和预后
考核模型系统,包括来自患者血清的宿主IgG/IgM、标准合成囊泡(SV)和
热灭活的SARS-CoV-2病毒颗粒(SVV)将被设计并加入生物液体中,以验证和
校准系统。为了证明临床实用性,我们的生物芯片技术将使用
在两个独立的实验室中,来自COVID-19患者的不同生物流体(
西雅图和哥伦布的俄亥俄州州立大学(OSU)Wexner医学中心)。获得的测量
将来自生物芯片的检测结果与标准qRT-PCR和ELISA方法进行比较。将制定过渡计划
通过COVID-19临床试验申请FDA紧急使用授权(EUA)生物芯片技术
OSU Wexner医疗中心的检测实验室。还将通过许可制定商业化计划
一家生物科技公司
我们已经组建了一个多学科的团队,在纳米生物技术方面拥有丰富的知识和经验,
微流体、微/纳米制造、传染病和临床COVID-19患者样本采集,
试验.拟议的目标和里程碑如下:
具体目标1:开发集成生物芯片,同时捕获,固定和表征
单一SARS-CoV-2和IgG/IgM蛋白。Mildly. (i)分类、捕获和定量分析
在加标实验中,单一病毒中的选定蛋白质和病毒RNA具有>95%的可重复性;(ii)
单一病毒检测,重复性>90%,灵敏度比当前的qRT-PCR和ELISA高5倍
方法.具体目标2:检测来自以下国家的生物液体中的单一SARS-CoV-2病毒和相关IgG/IgM
2019冠状病毒病患者。Mildly. (i)临床样品的定量分析,重复性>95%;(ii)95%
生物芯片技术与实验室qRT-PCR检测SARS-CoV-2的一致性
和ELISA。具体目标3:生物芯片技术转型计划。Mildly. (i)提交文件
向FDA器械和放射卫生中心(CDRH)提交EUA;(ii)
GMP芯片生产。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Microfluidic harvesting of breast cancer tumor spheroid-derived extracellular vesicles from immobilized microgels for single-vesicle analysis.
- DOI:10.1039/d1lc01053k
- 发表时间:2022-06-28
- 期刊:
- 影响因子:6.1
- 作者:
- 通讯作者:
Engineering a tunable micropattern-array assay to sort single extracellular vesicles and particles to detect RNA and protein in situ.
- DOI:10.1002/jev2.12369
- 发表时间:2023-11
- 期刊:
- 影响因子:16
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Inyoul Lee其他文献
Inyoul Lee的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
- 批准号:Y24H280055
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
- 批准号:82373169
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
- 批准号:82330111
- 批准年份:2023
- 资助金额:220 万元
- 项目类别:重点项目
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
- 批准号:32300137
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于AT2/ACE2/Ang(1-7)/MAS轴调控心脏-血管-血液系统性重构演变规律研究心衰气虚血瘀证及其益气通脉活血化瘀治法生物学基础
- 批准号:82305216
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于外泌体miRNAs介导细胞通讯的大豆ACE2激活肽调控血管稳态机制研究
- 批准号:32302080
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
感毒清经ACE2/Ang(1-7)/MasR信号通路抑制PM2.5诱导慢性气道炎症的机制:聚焦肺泡巨噬细胞极化与“胞葬”的表型串扰
- 批准号:82305171
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
刺参自溶引发机制中ACE2调控靶点的调控网络研究
- 批准号:32372399
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
Spike变异对新冠病毒抗原性及ACE2种属嗜性的影响研究
- 批准号:82272305
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
新型コロナウイルス感染阻害能を有する抗ACE2抗体の阻害機構に関する構造基盤解明
阐明具有抑制新型冠状病毒感染能力的抗ACE2抗体抑制机制的结构基础
- 批准号:
24K09338 - 财政年份:2024
- 资助金额:
$ 87.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ACE2のユビキチン化を介したコロナウイルス感染機構の解明と創薬への挑戦
通过ACE2泛素化阐明冠状病毒感染机制和药物发现的挑战
- 批准号:
22KJ2499 - 财政年份:2023
- 资助金额:
$ 87.9万 - 项目类别:
Grant-in-Aid for JSPS Fellows
ACE2阻害薬およびERK経路阻害薬による慢性腎炎進展抑制効果の検証
ACE2抑制剂和ERK通路抑制剂抑制慢性肾炎进展的效果验证
- 批准号:
23K14982 - 财政年份:2023
- 资助金额:
$ 87.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Large-scale compatibility assessments between ACE2 proteins and diverse sarbecovirus spikes
ACE2 蛋白和多种 sarbecovirus 尖峰之间的大规模兼容性评估
- 批准号:
10722852 - 财政年份:2023
- 资助金额:
$ 87.9万 - 项目类别:
一次線毛とコロナウイルス感染におけるACE2の役割の解明
阐明 ACE2 在原发菌毛和冠状病毒感染中的作用
- 批准号:
22KF0004 - 财政年份:2023
- 资助金额:
$ 87.9万 - 项目类别:
Grant-in-Aid for JSPS Fellows
The regulatory roles of ACE2 and its interaction with Nrf2 in arsenic-induced endothelial dysfunction in experimental and epidemiological studies
实验和流行病学研究中 ACE2 的调节作用及其与 Nrf2 的相互作用在砷诱导的内皮功能障碍中的作用
- 批准号:
23K16310 - 财政年份:2023
- 资助金额:
$ 87.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of ACE2 in the mechanism of intestinal regeneration
ACE2在肠道再生机制中的作用
- 批准号:
23K15078 - 财政年份:2023
- 资助金额:
$ 87.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Research and development of a novel pediatric anti-obesity medicine via ACE2 activation in DIZE
通过 DIZE 中 ACE2 激活研发新型儿科抗肥胖药物
- 批准号:
23K15417 - 财政年份:2023
- 资助金额:
$ 87.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Lung delivery of novel ACE2 variants for COVID-19
针对 COVID-19 的新型 ACE2 变体的肺部输送
- 批准号:
10483042 - 财政年份:2022
- 资助金额:
$ 87.9万 - 项目类别:
ACE2 on gut barrier dysfunction and BRB disruption
ACE2 对肠道屏障功能障碍和 BRB 破坏的影响
- 批准号:
10535485 - 财政年份:2022
- 资助金额:
$ 87.9万 - 项目类别: